Over the past two decades, GLP-1 RAs have become a cornerstone in the treatment algorithm for T2DM, especially in patients who require improved glycaemic control with the added benefit of weight reduction and cardiovascular protection. This evidence concerns the gene GCG and type 2 diabetes mellitus.